{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:09:02Z","timestamp":1789711742428,"version":"4.0.1"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Epidemiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prolonged \u03b2-lactam infusion is common in critical care, but whether continuous infusion (CI) improves outcomes more than extended infusion (EI) is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and random-effects Bayesian network meta-analysis of randomized controlled trials in critically ill adults comparing intravenous \u03b2-lactam administration by continuous infusion (24-hour infusion), extended infusion (\u22653\u2005h per dose), and intermittent infusion (\u22641\u2005h per dose). We searched PubMed, EMBASE, Web of Science, and the Cochrane Library from January 1, 2000, to July 25, 2025. Two reviewers independently screened records, extracted data, and assessed risk of bias. Relative risks (RRs) and mean differences (MDs) were synthesized using random-effects models. Network meta-analysis used Markov chain Monte Carlo methods in R, with complementary pairwise analyses in Stata. Certainty of evidence was assessed using GRADE for network meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-five randomized trials (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20099,915) were included; no direct CI vs. EI trials were identified. Versus II, CI reduced mortality (RR 0.85, 95% CI 0.66\u20130.98; moderate certainty); EI had uncertain mortality effects (RR 0.80, 95% CI 0.60\u20131.10; low certainty). Clinical cure improved versus II for CI (RR 1.10, 95% CI 1.03\u20131.20) and EI (RR 1.28, 95% CI 1.07\u20131.55). ICU length of stay was uncertain (CI vs. II: MD \u22120.47 days, 95% CI \u22122.10\u20131.28; EI vs. II: MD \u22121.32 days, 95% CI \u22124.65\u20132.52). Indirect CI vs. EI comparisons showed no significant differences in mortality (RR 1.06, 95% CI 0.73\u20131.44), clinical cure (RR 0.86, 95% CI 0.70\u20131.05), or ICU length of stay (MD 0.86 days, 95% CI \u22123.32\u20134.54). Bayesian posterior probability analysis suggested a 93.2% probability that EI is superior to CI for clinical cure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CI did not demonstrate greater clinical benefit than EI. CI can reduce patient mortality, and both CI and EI appear to improve clinical cure rates compared with II. CI conferred no additional benefit over EI, suggesting that EI may be sufficient as a prolonged-infusion strategy in clinical practice. However, this finding is based on indirect evidence. The apparent advantage of EI should therefore be regarded as hypothesis-generating and requires confirmation in adequately powered head-to-head randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42023452814<\/jats:ext-link>\n                      , PROSPERO CRD42023452814.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fepid.2026.1883520","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:36:55Z","timestamp":1789709815000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["\u03b2-lactam infusion strategies in critical illness: is continuous superior to extended infusion? A systematic review and network meta-analysis"],"prefix":"10.3389","volume":"6","author":[{"given":"Fei","family":"Peng","sequence":"first","affiliation":[{"name":"Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Tang","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Hu","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Kang","sequence":"additional","affiliation":[{"name":"School of Life Sciences and Chemical Engineering, Jiangsu Second Normal University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chang","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Sun","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Xie","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Qiu","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1097\/CCM.0000000000004155","article-title":"The epidemiology of sepsis in Chinese ICUs: a national cross-sectional survey","volume":"48","author":"Xie","year":"2020","journal-title":"Crit Care Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13054-023-04385-x","article-title":"National incidence and mortality of hospitalized sepsis in China","volume":"27","author":"Weng","year":"2023","journal-title":"Crit Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","article-title":"\u03b2-lactams and \u03b2-lactamase inhibitors: an overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1093\/jac\/dkv165","article-title":"The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs","volume":"70","author":"Tabah","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/jac\/dkad223","article-title":"The clinical application of beta-lactam antibiotic therapeutic drug monitoring in the critical care setting","volume":"78","author":"Pai Mangalore","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13054-018-2155-1","article-title":"Pharmacokinetics\u2013pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients","volume":"22","author":"Veiga","year":"2018","journal-title":"Crit Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/2110-5820-2-37","article-title":"Continuous beta-lactam infusion in critically ill patients: the clinical evidence","volume":"2","author":"Abdul-Aziz","year":"2012","journal-title":"Ann Intensive Care"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1007\/s00134-024-07650-x","article-title":"Continuous infusion of beta-lactam antibiotics in critically ill patients with sepsis: implementation considerations","volume":"50","author":"Barton","year":"2024","journal-title":"Intensive Care Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/phar.2842","article-title":"International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1001\/jama.2024.9803","article-title":"Prolonged vs. intermittent infusions of \u03b2-lactam antibiotics in adults with sepsis or septic shock: a systematic review and meta-analysis","volume":"332","author":"Abdul-Aziz","year":"2024","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","first-page":"114220","DOI":"10.1016\/j.jpeds.2024.114220","article-title":"Prolonged beta-lactam infusions in children: a systematic review and meta-analysis","volume":"275","author":"Briand","year":"2024","journal-title":"J Pediatr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"102634","DOI":"10.1016\/j.jiac.2025.102634","article-title":"Impact of prolonged versus intermittent infusion of meropenem on mortality and clinical outcomes in patients with severe infection: a systematic review and meta-analysis","volume":"31","author":"Mu","year":"2025","journal-title":"J Infect Chemother"},{"key":"B15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/QCO.0000000000000755","article-title":"Continuous versus intermittent infusion of antibiotics in gram-negative multidrug-resistant infections","volume":"34","author":"Gatti","year":"2021","journal-title":"Curr Opin Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Stat Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2023.03.003","article-title":"GRADE guidance 36: updates to GRADE\u2019s approach to addressing inconsistency","volume":"158","author":"Guyatt","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"CMAJ"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e074495","DOI":"10.1136\/bmj-2022-074495","article-title":"A guide and pragmatic considerations for applying GRADE to network meta-analysis","volume":"381","author":"Izcovich","year":"2023","journal-title":"Br Med J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"360","DOI":"10.5414\/CPP43360","article-title":"Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen","volume":"43","author":"Georges","year":"2005","journal-title":"CP"},{"key":"B24","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ijantimicag.2014.05.011","article-title":"Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions","volume":"44","author":"Lip\u0161","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"B25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4103\/sja.SJA_148_17","article-title":"Effect of extended infusion of meropenem and nebulized amikacin on gram-negative multidrug-resistant ventilator-associated pneumonia","volume":"12","author":"Ammar","year":"2018","journal-title":"Saudi J Anaesth"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","article-title":"Beta-lactam infusion in severe sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis","volume":"42","author":"Abdul-Aziz","year":"2016","journal-title":"Intensive Care Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10096-016-2819-1","article-title":"Clinical outcomes of extended versus intermittent administration of piperacillin\/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial","volume":"36","author":"Bao","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/phar.1875","article-title":"Clinical outcomes of extended versus intermittent infusion of piperacillin\/tazobactam in critically ill patients: a prospective clinical trial","volume":"37","author":"Fan","year":"2017","journal-title":"Pharmacotherapy"},{"key":"B29","doi-asserted-by":"publisher","first-page":"154170","DOI":"10.1016\/j.jcrc.2022.154170","article-title":"The clinical and paraclinical effectiveness of four-hour infusion vs. half-hour infusion of high-dose ampicillin-sulbactam in treatment of critically ill patients with sepsis or septic shock: an assessor-blinded randomized clinical trial","volume":"73","author":"Mirjalili","year":"2023","journal-title":"J Crit Care"},{"key":"B30","doi-asserted-by":"publisher","first-page":"10882","DOI":"10.1038\/s41598-022-12861-7","article-title":"Extended infusion of piperacillin\u2013tazobactam versus intermittent infusion in critically ill Egyptian patients: a cost-effectiveness study","volume":"12","author":"Naiim","year":"2022","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1592\/phco.21.6.549.34539","article-title":"Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia","volume":"21","author":"McNabb","year":"2001","journal-title":"Pharmacotherapy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/antibiotics13030229","article-title":"Efficacy of continuous vs. intermittent administration of cefepime in adult ICU patients with gram-negative Bacilli bacteremia: a randomized double-blind clinical study","volume":"13","author":"\u00c1lvarez-Moreno","year":"2024","journal-title":"Antibiotics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"106487","DOI":"10.1016\/j.jinf.2025.106487","article-title":"Continuous versus intermittent bolus dosing of beta-lactam antibiotics in a South African multi-disciplinary intensive care unit: a randomized controlled trial","volume":"90","author":"Khan","year":"2025","journal-title":"J Infect"},{"key":"B34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/FTD.0000000000001144","article-title":"A randomized clinical trial of Bayesian-guided beta-lactam infusion strategy and associated bacterial resistance and clinical outcomes in patients with severe pneumonia","volume":"46","author":"Maranchick","year":"2024","journal-title":"Ther Drug Monit"},{"key":"B35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jama.2024.9779","article-title":"Continuous vs. intermittent \u03b2-lactam antibiotic infusions in critically ill patients with sepsis: the BLING III randomized clinical trial","volume":"332","author":"Dulhunty","year":"2024","journal-title":"JAMA"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.4103\/0366-6999.205859","article-title":"Pharmacokinetic and pharmacodynamic efficacies of continuous versus intermittent administration of meropenem in patients with severe sepsis and septic shock: a prospective randomized pilot study","volume":"130","author":"Zhao","year":"2017","journal-title":"Chin Med J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1128\/AAC.01318-06","article-title":"Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial","volume":"51","author":"Sakka","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"B38","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/jac\/dkl478","article-title":"Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study","volume":"59","author":"Roberts","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"B39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijantimicag.2006.02.020","article-title":"Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients","volume":"28","author":"Rafati","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"B40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/jama.2023.10598","article-title":"Continuous vs. intermittent meropenem administration in critically ill patients with sepsis: the MERCY randomized clinical trial","volume":"330","author":"Monti","year":"2023","journal-title":"JAMA"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1128\/AAC.00329-06","article-title":"Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection","volume":"50","author":"Lau","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"B42","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/jac\/dku465","article-title":"Temocillin (6g daily) in critically ill patients: continuous infusion versus three times daily administration","volume":"70","author":"Laterre","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1164\/rccm.201505-0857OC","article-title":"A multicenter randomized trial of continuous versus intermittent \u03b2-lactam infusion in severe sepsis","volume":"192","author":"Dulhunty","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/cid\/cis856","article-title":"Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial","volume":"56","author":"Dulhunty","year":"2013","journal-title":"Clin Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11096-015-0208-y","article-title":"Continuous versus intermittent piperacillin\/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa","volume":"38","author":"Cotrina-Luque","year":"2016","journal-title":"Int J Clin Pharm"},{"key":"B46","doi-asserted-by":"publisher","first-page":"R113","DOI":"10.1186\/cc11405","article-title":"Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial","volume":"16","author":"Chytra","year":"2012","journal-title":"Crit Care"},{"key":"B47","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1365-2125.2000.00179.x","article-title":"Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs. intermittent bolus injection in septicaemic melioidosis","volume":"50","author":"Angus","year":"2000","journal-title":"Brit J Clinical Pharma"},{"key":"B48","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0924-8579(01)00329-6","article-title":"Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia","volume":"17","author":"Nicolau","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"B49","doi-asserted-by":"publisher","first-page":"w14368","DOI":"10.4414\/smw.2016.14368","article-title":"Prolonged administration of \u03b2-lactam antibiotics \u2013 a comprehensive review and critical appraisal","volume":"146","author":"Osthoff","year":"2016","journal-title":"Swiss Med Wkly"},{"key":"B50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/2110-5820-2-22","article-title":"Continuous infusion of antibiotics in the critically ill: the new holy grail for beta-lactams and vancomycin?","volume":"2","author":"Van Herendael","year":"2012","journal-title":"Ann Intensive Care"},{"key":"B51","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of \u03b2-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"B52","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00134-021-06609-6","article-title":"Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial","volume":"48","author":"Hagel","year":"2022","journal-title":"Intensive Care Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/ejhpharm-2023-003855","article-title":"Systematic review of room temperature stability of key beta-lactam antibiotics for extended infusions in inpatient settings","volume":"31","author":"Jenkins","year":"2024","journal-title":"Eur J Hosp Pharm"},{"key":"B54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13613-023-01222-w","article-title":"Prolonged vs. intermittent intravenous infusion of \u03b2-lactam antibiotics for patients with sepsis: a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis","volume":"13","author":"Li","year":"2023","journal-title":"Ann Intensive Care"}],"container-title":["Frontiers in Epidemiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fepid.2026.1883520\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:36:56Z","timestamp":1789709816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fepid.2026.1883520\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":54,"alternative-id":["10.3389\/fepid.2026.1883520"],"URL":"https:\/\/doi.org\/10.3389\/fepid.2026.1883520","relation":{},"ISSN":["2674-1199"],"issn-type":[{"value":"2674-1199","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1883520"}}